Showing posts with label Amifostine. Show all posts
Showing posts with label Amifostine. Show all posts
Wednesday, March 30, 2011
EvidenceUpdates - Interventions for preventing neuropathy caused by cisplatin and related compounds
BACKGROUND:
Cisplatin and several related antineoplastic agents used to treat many types of solid tumors are neurotoxic, and most patients completing a full course of cisplatin chemotherapy develop a clinically detectable sensory neuropathy. Effective neuroprotective therapies have been sought.
AUTHORS' CONCLUSIONS:
At present, the data are insufficient to conclude that any of the purported chemoprotective agents (acetylcysteine, amifostine, calcium and magnesium, diethyldithiocarbamate, glutathione, Org 2766, oxycarbazepine, or Vitamin E) prevent or limit the neurotoxicity of platin drugs among human patients.
add your opinions
acetylcysteine
,
Amifostine
,
calcium and magnesium
,
Cisplatin
,
diethyldithiocarbamate
,
glutathione
,
neuropathy
,
neurotoxicity
,
Org 2766
,
oxycarbazepine
,
solid tumors
,
vitamin E
Friday, March 04, 2011
Cochrane review: Interventions for preventing neuropathy caused by cisplatin and related compounds
AUTHORS' CONCLUSIONS: At present, the data are insufficient to conclude that any of the purported chemoprotective agents (acetylcysteine, amifostine, calcium and magnesium, diethyldithiocarbamate, glutathione, Org 2766, oxycarbazepine, or Vitamin E) prevent or limit the neurotoxicity of platin drugs among human patients.
add your opinions
Amifostine
,
calcium
,
chemoprotection
,
Cisplatin
,
Glutathione peroxidase 3
,
magnesium
,
neurotoxicity
,
platinum
,
vitamin E
Thursday, January 14, 2010
Subscribe to:
Posts
(
Atom
)